The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alternative splicing (AS) regulation as a novel therapeutic target in soft-tissue sarcoma (STS).
 
David Silva Moura
Honoraria - Tecnofarma
Research Funding - Eisai (Inst); Immix BioPharma (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Pfizer; PharmaMar
 
Esther Martinez-Font
No Relationships to Disclose
 
Carine Bossard
Employment - Biosplice; Sorrento Therapeutics (I)
Stock and Other Ownership Interests - Sorrento Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Listed as an inventor in 2 Samumed pending U.S. applications; Listed as an inventor in several pending patent applications and patents from Ambrx and Sorrento Therapeutics (I)
Travel, Accommodations, Expenses - Biosplice
 
Antonio Rubio-Reyes
No Relationships to Disclose
 
Jose Lucinio Mondaza-Hernandez
No Relationships to Disclose
 
Marta Martin-Ruiz
No Relationships to Disclose
 
Pablo Romero-Gonzalez
No Relationships to Disclose
 
Marta Renshaw-Calderon
No Relationships to Disclose
 
Jaime Carrillo-Garcia
No Relationships to Disclose
 
Davide Di Lernia
No Relationships to Disclose
 
Nadia Hindi
Honoraria - PharmaMar; Tecnofarma
Consulting or Advisory Role - GlaxoSmithKline; PharmaMar
Research Funding - Adaptimmune (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Pfizer (Inst); CEBIOTEX (Inst); Deciphera (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Antonia Obrador
No Relationships to Disclose
 
Javier Martin Broto
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar